Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) - Equities researchers at B. Riley issued their Q1 2025 earnings per share (EPS) estimates for shares of Viridian Therapeutics in a note issued to investors on Monday, March 3rd. B. Riley analyst K. Patel expects that the company will earn ($1.09) per share for the quarter. The consensus estimate for Viridian Therapeutics' current full-year earnings is ($4.03) per share. B. Riley also issued estimates for Viridian Therapeutics' Q3 2025 earnings at ($1.21) EPS, Q4 2025 earnings at ($1.30) EPS, FY2025 earnings at ($4.74) EPS, FY2026 earnings at ($4.95) EPS, FY2027 earnings at ($3.61) EPS and FY2028 earnings at ($2.64) EPS.
Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.81) earnings per share for the quarter, topping analysts' consensus estimates of ($1.05) by $0.24. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. The business had revenue of $0.07 million for the quarter, compared to analysts' expectations of $0.05 million.
A number of other research analysts have also issued reports on VRDN. Royal Bank of Canada boosted their price target on Viridian Therapeutics from $44.00 to $47.00 and gave the stock an "outperform" rating in a research report on Tuesday, December 17th. HC Wainwright reissued a "buy" rating and set a $34.00 target price on shares of Viridian Therapeutics in a research note on Monday, December 16th. Wells Fargo & Company restated an "equal weight" rating and set a $27.00 price target (down from $37.00) on shares of Viridian Therapeutics in a research report on Thursday, December 19th. Needham & Company LLC reiterated a "buy" rating and issued a $38.00 price objective on shares of Viridian Therapeutics in a report on Tuesday, January 7th. Finally, TD Cowen assumed coverage on Viridian Therapeutics in a report on Monday, November 25th. They set a "buy" rating on the stock. Three equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, Viridian Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $35.70.
Get Our Latest Stock Report on VRDN
Viridian Therapeutics Stock Performance
Shares of NASDAQ VRDN traded up $0.06 during midday trading on Wednesday, hitting $15.94. 1,008,783 shares of the company's stock were exchanged, compared to its average volume of 1,184,738. Viridian Therapeutics has a twelve month low of $11.40 and a twelve month high of $27.20. The firm has a market cap of $1.26 billion, a P/E ratio of -3.70 and a beta of 1.05. The stock's 50 day moving average price is $17.79 and its 200-day moving average price is $19.67. The company has a debt-to-equity ratio of 0.04, a current ratio of 18.55 and a quick ratio of 18.55.
Institutional Investors Weigh In On Viridian Therapeutics
Large investors have recently modified their holdings of the stock. FMR LLC raised its position in shares of Viridian Therapeutics by 6.2% during the fourth quarter. FMR LLC now owns 11,881,912 shares of the company's stock worth $227,776,000 after purchasing an additional 698,434 shares during the period. Vanguard Group Inc. raised its holdings in Viridian Therapeutics by 4.0% during the 4th quarter. Vanguard Group Inc. now owns 4,595,049 shares of the company's stock worth $88,087,000 after buying an additional 174,952 shares during the period. Deep Track Capital LP lifted its stake in Viridian Therapeutics by 20.6% during the fourth quarter. Deep Track Capital LP now owns 4,522,741 shares of the company's stock valued at $86,701,000 after buying an additional 771,796 shares in the last quarter. Tang Capital Management LLC boosted its holdings in shares of Viridian Therapeutics by 11.1% in the fourth quarter. Tang Capital Management LLC now owns 2,492,925 shares of the company's stock worth $47,789,000 after buying an additional 250,000 shares during the period. Finally, Alliancebernstein L.P. increased its position in shares of Viridian Therapeutics by 3.8% in the fourth quarter. Alliancebernstein L.P. now owns 2,286,994 shares of the company's stock worth $43,842,000 after acquiring an additional 84,255 shares in the last quarter.
About Viridian Therapeutics
(
Get Free Report)
Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.
Featured Stories
Before you consider Viridian Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viridian Therapeutics wasn't on the list.
While Viridian Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
